
    
      This is a multicentric, open-label, single-arm prospective study to assess the efficacy and
      safety of tislelizumab combined with conventional transarterial chemoembolization(cTACE) as
      first-line treatment in BCLC stage C HCC patients without extrahepatic spread. The primary
      endpoint is time to progression (TTP).
    
  